REGEN BIOPHARMA, INC.: 10-K filed 2023-11-20

Name: REGEN BIOPHARMA, INC.: 10-K filed 2023-11-20
Creator: REGEN BIOPHARMA, INC.

What REGEN BIOPHARMA, INC. reported in its annual report filed 2023-11-20 (fiscal FY 2023): 31 published measures, 74 facts as tagged in accession 0001607062-23-000524.

This filing

Form: 10-K (annual report)
Filed: 2023-11-20
Fiscal period: fiscal FY 2023
Accession: 0001607062-23-000524 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All REGEN BIOPHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2023-09-30	353,617	USD
At 2022-09-30	559,002	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2023-09-30	5,457,617	USD
At 2022-09-30	8,595,061	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2023-09-30	-5,104,000	USD
At 2023-06-30	-5,028,973	USD
At 2023-03-31	-4,929,755	USD
At 2022-12-31	-4,884,827	USD
At 2022-09-30	-8,036,059	USD
At 2022-06-30	-8,349,684	USD
At 2022-03-31	-76,749,430	USD
At 2021-12-31	-9,755,969	USD
At 2021-09-30	-13,485,877	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	1,156,507	USD	365
2021-10-01 to 2022-09-30	2,443,531	USD	365

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	-173,917	USD	365
2021-10-01 to 2022-09-30	-606,921	USD	365

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	126,560	USD	365
2021-10-01 to 2022-09-30	125,517	USD	365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	243,750	USD	365
2021-10-01 to 2022-09-30	-94,036	USD	365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2021-10-01 to 2022-09-30	25,000	USD	365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2023-09-30	-19,748,863	USD
At 2022-09-30	-20,905,369	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	3,536,963	shares	365
2021-10-01 to 2022-09-30	3,135,846	shares	365

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	3,536,963	shares	365
2021-10-01 to 2022-09-30	3,135,846	shares	365

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	0.29	USD/shares	365
2021-10-01 to 2022-09-30	0.7102	USD/shares	365

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	0.29	USD/shares	365
2021-10-01 to 2022-09-30	0.7102	USD/shares	365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	-686,950	USD	365
2021-10-01 to 2022-09-30	-339,605	USD	365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2023-09-30	131,037	USD
At 2022-09-30	336,422	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	58,584	USD	365
2021-10-01 to 2022-09-30	138,720	USD	365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2023-09-30	5,308,003	USD
At 2022-09-30	8,595,061	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2023-09-30	29,674	USD
At 2022-09-30	28,799	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit	Days
At 2023-09-30	0	USD
At 2022-09-30	254,273	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	212,297	USD	365
2021-10-01 to 2022-09-30	158,138	USD	365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2023-09-30	3,506,366	shares
At 2022-09-30	3,354,866	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2023-09-30	121,037	USD
At 2022-09-30	51,204	USD
At 2021-09-30	727,162	USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2023-09-30	13,908,141	USD
At 2022-09-30	11,581,499	USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

Period	Value	Unit	Days
At 2023-09-30	-5,104,000	USD
At 2022-09-30	-8,036,059	USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

Period	Value	Unit	Days
At 2023-09-30	0	USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-325,027	USD	92
2023-04-01 to 2023-06-30	-99,218	USD	91
2023-01-01 to 2023-03-31	-54,978	USD	90
2022-10-01 to 2022-12-31	1,635,730	USD	92
2022-07-01 to 2022-09-30	-78,027	USD	92
2022-04-01 to 2022-06-30	66,958,167	USD	91
2022-01-01 to 2022-03-31	-67,081,589	USD	90
2021-10-01 to 2021-12-31	2,644,980	USD	92

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	1,023,508	USD	365
2021-10-01 to 2022-09-30	2,227,034	USD	365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	44,975	USD	365
2021-10-01 to 2022-09-30	28,055	USD	365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	1,843,456	USD	365
2021-10-01 to 2022-09-30	2,783,136	USD	365

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	-254,272	USD	365
2021-10-01 to 2022-09-30	41,082	USD	365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2022-10-01 to 2023-09-30	875	USD	365
2021-10-01 to 2022-09-30	-62,705	USD	365

Inspect the source

Entity: REGEN BIOPHARMA, INC. / CIK 0001589150
Captured: 2026-09-20T09:23:48.532Z
SEC response SHA-256: 0bbe246b6080c7701ba978807745a4ba9de62971ab4db32e8d3e2fa2c4f26a87

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001589150.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))